NCT06481579View on ClinicalTrials.gov

A Study of IVX-A12 in Adults Participants

PHASE2CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

June 10, 2024

Primary Completion Date

July 17, 2024

Study Completion Date

December 19, 2024

Conditions
Healthy Participants
Interventions
BIOLOGICAL

IVX-A12

IVX-A12 IM injection.

BIOLOGICAL

Licensed RSV Vaccine

Licensed RSV Vaccine (AREXVY) IM injection.

Trial Locations (5)

29405

Icosavax Investigational Site US016, North Charleston

33024

Icosavax Investigational Site US002, Hollywood

66219

Icosavax Investigational Site US011, Lenexa

90274

Icosavax Investigational Site US021, Rolling Hills Estates

92801

Icosavax Investigational Site US022, Anaheim

Sponsors

Lead Sponsor

Icosavax, Inc.
All Listed Sponsors
lead

Icosavax, Inc.

INDUSTRY

NCT06481579 - A Study of IVX-A12 in Adults Participants | Biotech Hunter | Biotech Hunter